Author

Gábor Tamás Tóth 1

1 Fovarosi Onkormanyzat Szent Janos

BIOSIMILAR INFLIXIMAB: EFFICACY AND SAFETY BASED ON INTERIM RESULTS FROM A PROSPECTIVE NATIONWIDE COHORT

Krisztina Barbara Gecse, Klaudia Farkas, Barbara Dorottya Lovasz, János Banai, László Bene, Beata Gasztonyi, Petra Anna Golovics, Tünde Kristóf, Peter L Lakatos, Pal Miheller, Ferenc Nagy, Karoly Palatka, Mária Papp, Árpád V. Patai, Ágnes Szabone Salamon, Tamás Szamosi, Zoltan Gabor Szepes, Gábor Tamás Tóth, Aron Vincze;;

CLINICAL EFFICACY, DRUG SUSTAINABILITY AND RESULTS FROM THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB - 1-YEAR FOLLOW-UP OF A PROSPECTIVE, NATIONWIDE, MULTICENTER COHORT FROM HUNGARY

Lorant Gonczi, Kata Szántó, Klaudia Farkas, Tamás Molnár, Tamás Szamosi, Eszter Schäfer, Petra Anna Golovics, Barbara Dorottya Lovasz, Mark Juhasz, Árpád V. Patai, Aron Vincze, Patrícia Sarlós, Karoly Palatka, Alexandra Farkas, Gábor Tamás Tóth, Peter L Lakatos, Pal Miheller, Ákos Iliás

EFFICACY AND SAFETY OF BIOSIMILAR INFLIXIMAB AFTER ONE-YEAR: RESULTS FROM A PROSPECTIVE NATIONWIDE COHORT

Krisztina Barbara Gecse, Zsuzsanna Vegh, Zsuzsanna Kürti, Mariann Rutka, Klaudia Farkas, János Banai, László Bene, Beata Gasztonyi, Petra Anna Golovics, Barbara Dorottya Lovasz, Tünde Kristóf, László Lakatos, Pal Miheller, Ferenc Nagy, Karoly Palatka, Mária Papp, Lilla Laura Lakner, Árpád V. Patai, Ágnes Szabone Salamon;;

FINAL RESULTS ON EFFICACY AND SAFETY OF BIOSIMILAR INFLIXIMAB AFTER ONE-YEAR: RESULTS FROM A PROSPECTIVE NATIONWIDE COHORT

Krisztina Barbara Gecse, Zsuzsanna Vegh, Zsuzsanna Kürti, Mariann Rutka, Klaudia Farkas, Petra Anna Golovics, Barbara Dorottya Lovasz, Lorant Gonczi, János Banai, László Bene, Beata Gasztonyi, Tünde Kristóf, László Lakatos, Pal Miheller, Ferenc Nagy, Karoly Palatka, Mária Papp, Árpád V. Patai, Ágnes Szabone Salamon, Tamá

FINAL RESULTS ON IMMUNOGENICITY PROFILE AND PREDICTORS OF ADA DEVELOPMENT OF BIOSIMILAR INFLIXIMAB DURING THE FIRST 12 MONTHS OF THE THERAPY: RESULTS FROM A PROSPECTIVE NATIONWIDE COHORT

Petra Anna Golovics, Barbara Dorottya Lovasz, Zsuzsanna Kürti, Mariann Rutka, Zsuzsanna Vegh, Krisztina Barbara Gecse, Klaudia Farkas, János Banai, László Bene, Lorant Gonczi, Beata Gasztonyi, Tünde Kristóf, László Lakatos, Pal Miheller, Karoly Palatka, Árpád V. Patai, Mária Papp, Ágnes Szabone Salamon, Tamás Szamosi, Zo

FREQUENCY AND CHARACTERISTICS OF INFUSION REACTIONS DURING BIOSIMILAR INFLIXIMAB TREATMENT IN INFLAMMATORY BOWEL DISEASES: RESULTS FROM CENTRAL EUROPEAN NATIONWIDE COHORT

Anita Balint, Mariann Rutka, Zsuzsanna Vegh, Zsuzsanna Kürti, Krisztina Barbara Gecse, János Banai, László Bene, Beata Gasztonyi, Tünde Kristóf, László Lakatos, Pal Miheller, Karoly Palatka, Árpád V. Patai, Ágnes Szabone Salamon, Tamás Szamosi, Zoltan Gabor Szepes, Gábor Tamás Tóth, Aron Vincze, Renáta Bor, Ágnes Milassi

IMA-638 IN ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY FROM A PHASE IIA MULTICENTER STUDY

Walter Reinisch, Julian Panés, Michael P De Micco, Beth Hanlon, Gábor Tamás Tóth, Plamen Petrov, Guojun Yuan, Fei Hua, Michelle Hinz, Karen Page, Tara McDonnell, Peter Gruer, Fabio Cataldi

IMMUNOGENICITY OF THE BIOSIMILAR INFLIXIMAB: INTERIM RESULTS FROM A PROSPECTIVE NATIONWIDE COHORT

Barbara Dorottya Lovasz, Krisztina Barbara Gecse, Klaudia Farkas, János Banai, László Bene, Beata Gasztonyi, Petra Anna Golovics, Tünde Kristóf, Peter L Lakatos, Pal Miheller, Ferenc Nagy, Karoly Palatka, Mária Papp, Árpád V. Patai, Ágnes Szabone Salamon, Tamás Szamosi, Zoltan Gabor Szepes, Gábor Tamás Tóth, Aron Vincze;;

IMMUNOGENICITY PROFILE AND PREDICTORS OF TLS AND ADA DEVELOPMENT OF BIOSIMILAR INFLIXIMAB DURING THE FIRST 6 MONTHS OF THE THERAPY: RESULTS FROM A PROSPECTIVE NATIONWIDE COHORT

Barbara Dorottya Lovasz, Zsuzsanna Kürti, Mariann Rutka, Zsuzsanna Vegh, Krisztina Barbara Gecse, Petra Anna Golovics, Klaudia Farkas, János Banai, László Bene, Beata Gasztonyi, Tünde Kristóf, László Lakatos, Pal Miheller, Karoly Palatka, Árpád V. Patai, Ágnes Szabone Salamon, Tamás Szamosi, Zoltan Gabor Szepes, Edina Bir

PREDICTING OF SHORT AND MEDIUM-TERM EFFICACY OF BIOSIMILAR INFLIXIMAB THERAPY.  DO TROUGH LEVELS/ADAS OR CLINICAL/BIOCHEMICAL MARKERS PLAY A MORE IMPORTANT ROLE?

Petra Anna Golovics, Zsuzsanna Vegh, Mariann Rutka, Krisztina Barbara Gecse, Anita Balint, Klaudia Farkas, János Banai, László Bene, Beata Gasztonyi, Tünde Kristóf, László Lakatos, Pal Miheller, Karoly Palatka, Árpád V. Patai, Ágnes Szabone Salamon, Tamás Szamosi, Zoltan Gabor Szepes, Gábor Tamás Tóth, Aron Vincze, Edina

Item 1 - 10 / 11
1
2